Posted by Michael Wonder on 07 Aug 2024
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
8 August 2024 - Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Abaloparatide (Eladynos, Theramex) increases bone density by stimulating the cells that make new bone and this reduces the risk of fracture. It can provide an alternative for people who have not responded to, or cannot tolerate, usual treatment options.
